09:28 AM EST - Oncolytics Biotech Inc : Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium, which is being held at the Henry B. González Convention Center in San Antonio, Texas through December 10, 2022. Oncolytics Biotech Inc
shares T.ONC are trading -$0.05 at $2.35.
